enGene Therapeutics Warrants
ENGNW
15 hedge funds and large institutions have $4.02M invested in enGene Therapeutics Warrants in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 0 closing their positions.
7% more funds holding
Funds holding: 14 → 15 (+1)
1.07% less ownership
Funds ownership: 11.84% → 10.77% (-1.1%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
56% less capital invested
Capital invested by funds: $9.2M → $4.02M (-$5.18M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$23.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
-$701K |
| 2 |
SCM
Saba Capital Management
New York
|
-$20.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$562 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIS
1
FCPM III Services
Naarden,
Netherlands
| $2.43M | – | – | – |
|
|
BI
2
BVF Inc
San Francisco,
California
| $804K | – | – | – |
|
|
OFM
3
Omega Fund Management
Boston,
Massachusetts
| $271K | – | – | – |
|
|
SCM
4
Saba Capital Management
New York
| $150K | -$20.7K | -14,000 | -7% |
|
5
Calamos Advisors
Naperville,
Illinois
| $128K | – | – | – |
|
6
D.E. Shaw & Co
New York
| $88.9K | – | – | – |
|
|
TCM
7
Tenor Capital Management
New York
| $46.6K | – | – | – |
|
|
BOCH
8
Blue Owl Capital Holdings
New York
| $30.4K | -$701K | -475,077 | -93% |
|
|
WA
9
Whitebox Advisors
Minneapolis,
Minnesota
| $28.1K | – | – | – |
|
10
State of Wisconsin Investment Board
Madison,
Wisconsin
| $20K | – | – | – |
|
|
CL
11
CSS LLC
Chicago,
Illinois
| $14.2K | – | – | – |
|
|
WAM
12
Wolverine Asset Management
Chicago,
Illinois
| $13.4K | +$23.5K | +15,889 | New |
|
|
13
UBS Group
Zurich,
Switzerland
| $2.38K | -$562 | -381 | -12% |
|
14
Bank of America
Charlotte,
North Carolina
| $169 | – | – | – |
|
|
CS
15
Clear Street
New York
| $169 | – | – | – |
|
ENGNW Hedge Fund Activity: Q4 2024 in Review
15 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q4 2024, worth a combined $4.02M — down 56% from $9.2M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ENGNW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 3 trimmed.
The largest buyer was Wolverine Asset Management, opening a new position worth an estimated $23.5K. The largest seller was Blue Owl Capital Holdings, cutting an estimated $701K.
- 15 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q4 2024, up from 14 in Q3 2024.
- Funds reported $4.02M of enGene Therapeutics Warrants stock for Q4 2024, down 56% quarter-over-quarter.
- 1 fund opened new enGene Therapeutics Warrants positions in Q4 2024 and 0 closed out, a net change of +1 holder.
- The largest enGene Therapeutics Warrants buyer in Q4 2024 was Wolverine Asset Management, an estimated $23.5K added.
- The largest enGene Therapeutics Warrants seller in Q4 2024 was Blue Owl Capital Holdings, an estimated $701K sold.
Based on aggregated 13F filings for Q4 2024.